Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.44 |
| ▸ | PYGL | P06737 | 5/20 | 0.44 |
| ▸ | PYGM | P11217 | 5/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376337 | 1.00 | EPHX2 (0.44) | EPHX2RIPK1PYGLPYGMCRBN | |
| SCHEMBL5640963 | 0.86 | EPHX2 (0.56) | EPHX2RIPK1PYGLPYGMGAA | |
| SCHEMBL1269023 | 0.86 | EPHX2 (0.56) | EPHX2RIPK1PYGLPYGMGAA | |
| SCHEMBL1269022 | 0.86 | EPHX2 (0.56) | EPHX2RIPK1PYGLPYGMGAA | |
| SCHEMBL13783986 | 0.85 | RIPK1 (0.46) | EPHX2RIPK1PYGLPYGMGAA | |
| SCHEMBL3914513 | 0.84 | PYGL (0.53) | RIPK1PYGLPYGMCRBN | |
| SCHEMBL3989268 | 0.84 | PYGL (0.53) | RIPK1PYGLPYGMCRBN | |
| SCHEMBL1270295 | 0.84 | RIPK1 (0.58) | EPHX2RIPK1PYGLPYGMGAA | |
| SCHEMBL1270296 | 0.84 | RIPK1 (0.58) | EPHX2RIPK1PYGLPYGMGAA | |
| SCHEMBL12376347 | 0.84 | RIPK1 (0.52) | EPHX2RIPK1PYGLPYGMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994162-B2 | 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
| US-7994162-B2 | 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-04-16 | — | — | US | disclosed |
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-04-16 | — | — | US | disclosed |
| WO-2007135293-A2 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI AVENTIS (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | GABRA5, GABRA2, GABRA3 | EPHX2 239/4885RIPK1 4813/4885PYGL 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.